Coloplast playing it safe with new guidance due to inflation
The Danish medtech firm now risks failing to meet its long-term objectives, as revealed in the annual report for 2021/2022.
by marketwire, translated by daniel pedersen
In the worst-case scenario, Coloplast now has an outlook to an operating (EBIT) margin in skewed financial year 2022/2023 that falls short of the company’s long-term expectations due to inflation on energy and commodity prices, in particular.
An HR expert points to increasing competition for skilled workers combined with their pandemic fatigue as factors behind initiatives like Novo Nordisk’s advanced salary talks, Genmab’s extra day off a month, and Bavarian Nordic’s gift of four vacation days.